Experience With Anifrolumab In Systemic Lupus Erythematosus Patients With Neurological Manifestations
May 2025
in “
The Journal of Rheumatology
”
Studysummary This study reviewed how Anifrolumab, though often used in real-world settings for SLE patients with neurological symptoms, showed varying effectiveness and required cautious monitoring for adverse effects like thrombocytopenia and cerebrovascular events.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This study examines the use of Anifrolumab in 3 female patients with systemic lupus erythematosus (SLE) and neurological manifestations. Anifrolumab, typically not used in such cases during clinical trials, showed mixed results. In Case 1, a 29-year-old woman achieved disease remission and stopped corticosteroids after 6 months. Case 2 experienced adverse effects, including thrombocytopenia and a cerebrovascular event, leading to discontinuation of Anifrolumab. Case 3 achieved disease remission and did not require steroid pulses for 6 months. While Anifrolumab reduced corticosteroid use and managed lupus headaches, safety concerns necessitate further research on its use in patients with neurological involvement.
